On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026.
The board appointed Donn Casale, the company’s current president, as CEO and a director, effective July 7, 2026.
ARS Pharma CEO Change Was Not Entirely Unexpected: Analyst
William Blair on Thursday wrote, “While the move seems abrupt, we are not altogether surprised that the board may have been looking for a change given the stock performance over the past year on the back of a neffy launch that has not lived up to expectations.”
However, analyst Lachlan Hanbury-Brown viewed Casale’s appointment positively, citing his more than 25 years of commercial experience and his track record of building Dynavax Technologies’ Heplisav-B vaccine franchise into a market leader before the company was acquired by Sanofi.
